A Look into the 2025 Multiple Myeloma Landscape with Robert Orlowski, MD, PhD, MD Anderson Cancer Center
Event Description
This show will not be live streamed. You can submit your questions in advance by clicking the button "Notify when available."
The year 2025 brings new promise in multiple myeloma with a wide variety of treatment options avaiable for both newly diagnosed and relapsed/refractory patients. Learn about the progress being made and the very latest in determining risk at diagnosis, strategies for smoldering myeloma patients, optimal treatments for newly diagnosed patients, things to consider at first relapse and beyond. Dr. Robert Orlowski will review advances in CAR T therapies, bispecific antibodies, targeted therapies, combination approaches and clinical trials to watch as the research continues advancing at a rapid pace in myeloma.
Schedule & Agenda
Welcome, Announcements & Introduction
Welcome, Announcements & Introduction
An extensive discussion about the 2025 multiple myeloma landscape. We'll ask some of your previously submitted questions!
An extensive discussion about the 2025 multiple myeloma landscape. We'll ask some of your previously submitted questions!
Speakers & Moderators
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Robert Z. Orlowski, M.D., Ph.D., is Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, where he is board-certified in medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis School of Medicine. After his fellowships in Hematology and Medical Oncology at John Hopkins Sidney Kimmel Comprehensive Cancer Center, he joined the faculty at University of North Carolina in Chapel Hill. Following that, Dr. Orlowski accepted a position at The University of Texas MD Anderson Cancer Center in 2007 to lead the Myeloma Section in the Department of Lymphoma/Myeloma. His research interests include pathobiology of, novel therapeutic targets and mechanisms of drug resistance in myeloma which are documented in hundreds of scientific articles, book chapters, and presentations at conferences. Dr. Orlowski is an investigator on numerous clinical trials, and appointed Myeloma Committee Chair for SWOG.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
Stay Informed. Get the Support You Need for Multiple Myeloma.
By subscribing to the Healthtree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.